Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.41 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.41 |
| ▸ | CHRNG | P07510 | 1/20 | 0.41 |
| ▸ | CHRND | Q07001 | 1/20 | 0.41 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1828238 | 0.81 | HRH1 (0.40) | LMNA | |
| SCHEMBL11070013 | 0.80 | HRH1 (0.39) | LMNA | |
| SCHEMBL2083914 | 0.78 | CHRNB2 (0.69) | CHRNB2CHRNA4CYP11B2CHRNA3CHRNB4 | |
| SCHEMBL12520141 | 0.76 | CHRNB2 (0.67) | CHRNB2CHRNA4CYP11B2CHRNA3CHRNB4 | |
| SCHEMBL1830085 | 0.75 | HRH1 (0.41) | — | |
| SCHEMBL12949446 | 0.74 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL16845110 | 0.73 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL31276985 | 0.73 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL3168321 | 0.73 | SLC6A2 (0.47) | CHRNA3CHRNB4LMNA | |
| Hydrochloric Acid SCHEMBL16823577 | 0.73 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093668-A1 | N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-04-15 | — | — | US | disclosed |
| EP-2118092-A1 | NEW N, N'- 2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS | Sanofi-Aventis (FR) | 2009-11-18 | — | — | EP | disclosed |
| WO-2009056693-A1 | NOVEL DERIVATIVES OF N, N'- 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS MEDICAMENTS PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2009-05-07 | — | — | WO | disclosed |
| WO-2008099073-A1 | N, N' -2, 4-DIANILINOPYRIMIDINES PREPARATION AND USE THEREOF AS IKK INHIBITORS PREPARATION AND TEH PHARMACUETICAL COMPOSITIONS THEREOF | SANOFI-AVENTIS (FR) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093668-A1 | N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS | CHUK, IKBKB, IKBKE | CHRNB2 3442/4885CHRNA4 3764/4885CYP11B2 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.